Amgen expects key drugs like Repatha, Evenity, Tezspire and oncology and rare disease drugs, as well as biosimilars to drive ...

Repatha sales increased 36% in 2024, reaching over $2.2 billion in sales ... intent to purchase and administer this high-quality Amgen biosimilar, delivered in an easy-to-use prefilled syringe.

Overall, total sales of Ozempic and Wegovy were around DKK 53.7 billion in Q4 2024, an increase of 35.4% year-on-year. The second advantage of Amgen's product candidate is its efficacy.

Investing.com -- Fitch Ratings has revised its outlook for biopharmaceutical company Amgen Inc (NASDAQ: AMGN ). to positive ...

* The known adjustments are presented net of their related tax impact, which amount to approximately $1.54 per share. (a) The adjustments include noncash amortization of intangible assets and fair ...

The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently ...

Amgen reported stronger-than-expected Q4 2024 earnings, driven by a notable increase in product sales. The company projected 2025 revenue guidance, in range with average analyst consensus ...

are driving sales. Its total revenues rose 19% in 2024 to $33.4 billion. Amgen expects key drugs like Repatha, Evenity, Tezspire and oncology and rare disease drugs, as well as biosimilars to ...